Skip to main content
Premium Trial:

Request an Annual Quote

Sigma-Aldrich Licenses Epigentek IP for Upcoming Epigenetic Product Line

NEW YORK (GenomeWeb News) — Sigma-Aldrich today said it has licensed from Epigentek technology for DNA modification, methylation quantitation, and protein/DNA interaction, which Sigma plans to use to develop its planned epigenetics research products.
The license is exclusive in the US and co-exclusive globally, Sigma-Aldrich said.
Keith Jolliff, Sigma-Aldrich’s director of Genomics and Functional Genomics, said the agreement “is an excellent entry point to supporting epigenetics research,” which he said the company has identified “as a growing area of interest and research for heritable diseases such as cancer, Alzheimer’s, and many others.”
Sigma-Aldrich plans to launch a family of products for epigenetic research, beginning with the Imprint DNA Modification Kit, which it will launch this month. Other products planned under the Imprint brand include kits for global methylation quantitation and chromatin immunoprecipitation based on Epigentek's technologies.
Financial terms of the agreement were not disclosed.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.